PR Newswire12.16.20
CorVent Medical, a Coridea portfolio company focused on developing smart, reusable, lifesaving ventilators for critical care, announced an agreement with Siemens Healthineers for the U.S. distribution of the RESPOND-19 Ventilator to their network of hospital, healthcare system, and government customers. The RESPOND-19 Ventilator complements Siemens Healthineers offering of leading-edge technology by adding reliable, critical care respiratory support that expands ventilation capacity during surges in patient volume, such as during a flu season or pandemic.
"Our customers have experienced the impact of COVID-19 and recognize the need for on-demand ventilation that can be pulled out of storage and swiftly put to use," stated Dave Pacitti, Head of Americas at Siemens Healthineers. "As a leader in medical and diagnostic technology, we saw an opportunity to provide a comprehensive respiratory care solution by combining the innovative RESPOND-19 Ventilator with our portable x-ray technology and point-of-care blood gas solutions. We are excited to work with the CorVent team and anticipate a fruitful partnership that fills an ongoing market need."
The critical care RESPOND-19 Ventilator is designed to expand primary respiratory support capacity with rapid and affordable deployment to treat multiple patients during surges in patient demand. The sophisticated system offers mandatory, assist, and spontaneous ventilation modes along with built-in safeguards to meet the individual patient's needs. Optimized for multiple patient use, the system provides excellent infection control and out-of-the-box setup from long-term storage without ongoing service contracts or maintenance. The RESPOND-19 is ideal for disaster recovery or overflow ventilation needs and complements existing ventilator capacity to increase access to lifesaving respiratory support.
"This strategic agreement marks an important milestone for CorVent and positions RESPOND-19 as a disruptive technology that offers on-demand ventilation without costly service contracts or maintenance," commented Richard S. Walsh, CEO of CorVent Medical. "The U.S. is seeing a rise in COVID cases leading into flu season and many healthcare providers fear a strain on ventilator capacity. RESPOND-19 is designed to expand critical care ventilator capacity during these times of greatest need."
Earlier this month, CorVent received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RESPOND-19 Ventilator. In addition, the company stated they anticipate full FDA clearance of the system and CE Mark for European market access in 2021.
"Our customers have experienced the impact of COVID-19 and recognize the need for on-demand ventilation that can be pulled out of storage and swiftly put to use," stated Dave Pacitti, Head of Americas at Siemens Healthineers. "As a leader in medical and diagnostic technology, we saw an opportunity to provide a comprehensive respiratory care solution by combining the innovative RESPOND-19 Ventilator with our portable x-ray technology and point-of-care blood gas solutions. We are excited to work with the CorVent team and anticipate a fruitful partnership that fills an ongoing market need."
The critical care RESPOND-19 Ventilator is designed to expand primary respiratory support capacity with rapid and affordable deployment to treat multiple patients during surges in patient demand. The sophisticated system offers mandatory, assist, and spontaneous ventilation modes along with built-in safeguards to meet the individual patient's needs. Optimized for multiple patient use, the system provides excellent infection control and out-of-the-box setup from long-term storage without ongoing service contracts or maintenance. The RESPOND-19 is ideal for disaster recovery or overflow ventilation needs and complements existing ventilator capacity to increase access to lifesaving respiratory support.
"This strategic agreement marks an important milestone for CorVent and positions RESPOND-19 as a disruptive technology that offers on-demand ventilation without costly service contracts or maintenance," commented Richard S. Walsh, CEO of CorVent Medical. "The U.S. is seeing a rise in COVID cases leading into flu season and many healthcare providers fear a strain on ventilator capacity. RESPOND-19 is designed to expand critical care ventilator capacity during these times of greatest need."
Earlier this month, CorVent received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RESPOND-19 Ventilator. In addition, the company stated they anticipate full FDA clearance of the system and CE Mark for European market access in 2021.
